Search

Your search keyword '"Iarussi D"' showing total 175 results
Start Over Author "Iarussi D"
175 results on '"Iarussi D"'

1. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor

Author

Tripodi, M.F., Adinolfi, L.E., Ragone, E., Mangoni, E. Durante, Fortunato, R., Iarussi, D., Ruggiero, G., and Utili, R.

Subjects
Gram-positive bacteria -- Risk factors, Gram-positive bacteria -- Research, Streptococcal infections -- Care and treatment, Streptococcal infections -- Research, Endocarditis -- Care and treatment, Endocarditis -- Research, Streptococcus -- Risk factors, Streptococcus -- Research, Health, Health care industry
Published
2004

18. USE OF DOPPLER TISSUE IMAGING IN FEMALE CARRIERS OF DUCHENNE AND BECKER MUSCULAR DYSTROPHIES

Author

Agretto, Angelo, Bossone, E, D'Isa, S, Comi, L I., Politano, L, Iarussi, D, Iacono, A, and Erbel, R

Subjects
Duchenne muscular dystrophy -- Complications and side effects, Doppler ultrasonography, Becker muscular dystrophy -- Complications and side effects, Health, Complications and side effects
Abstract

Angelo Agretto, MD(*); E Bossone, MD; S D'Isa, MD; L I Comi, MD; L Politano, MD; D Iarussi, MD; A Iacono, MD and R Erbel, MD, FACC. Medical Surgical Institute [...]

Published
2000

19. DIASTOLIC AND SYSTOLIC FUNCTION IN BECKER MUSCULAR DYSTROPHY PATIENTS ASSESSED BY PULSED DOPPLER TISSUE IMAGING

Author

Agretto, Angelo, Bossone, E, D'Isa, S, Nigro, G, Petretta, V R., Iarussi, D, Signoriello, G, Iacono, A, and Erbel, R

Subjects
Diastole (Cardiac cycle) -- Physiological aspects -- Measurement, Cardiac output -- Measurement -- Physiological aspects, Becker muscular dystrophy -- Complications and side effects, Heart -- Contraction, Health, Physiological aspects, Complications and side effects, Measurement
Abstract

Angelo Agretto, MD(*); E Bossone, MD; S D'Isa, MD; G Nigro, MD; V R Petretta, MD; D Iarussi, MD; G Signoriello, MD; A Iacono, MD and R Erbel, MD, FACC. [...]

Published
2000

25. Non-HACEK gram-negative bacillus endocarditis.

Author

Delahaye F., Patel M., Dismukes W., Pan A., Caros G., Tribouilloy A.B.M.C., Ramallo V., Raoult D., Thuny F., Habib G., Casalta J.-P., Fournier P.-E., Chipigina N., Kirill O., Vinogradova T., Kulichenko V.P., Butkevich O.M., Lion C., Selton-Suty C., Alla F., Coyard H., Doco-Lecompte T., Durante-Mangoni E., Ragone E., Dialetto G., Tripodi M.F., Utili R., Casillo R., Kumar A.S., Sharma G., Street A., Eisen D.P., McBryde E.S., Grigg L., Abrutyn E., Michelet C., Donnio P.Y., Fortes C.Q., Edathodu J., Al-Hegelan M., Font B., Anguera I., Guma J.R., Cereceda M., Oyonarte M.J., Mella R.M., Garcia P., Jones S.B., Paiva M.G., Tranchesi R.A.D.M., Woon L.L., Lum L.-N., Tan R.-S., Rees D., Kornecny P., Lawrence R., Dever R., Post J., Jones P., Ryan S., Harkness J., Feneley M., Rubinstein E., Strahilewitz J., Ionac A., Mornos C., Dragulescu S., Forno D., Cecchi E., De Rosa F., Imazio M., Trinchero R., Wiesbauer F., Gattringer R., Deans G., Andrasevic A.T., Barsic B., Klinar I., Vincelj J., Bukovski S., Krajinovic V., Stafford J., Baloch K., Redick T., Harding T., Bayer A.S., Durack D.T., Moreillon P., Eykyn S., Morpeth S., Murdoch D., Cabell C.H., Karchmer A.W., Pappas P., Levine D., Nacinovich F., Tattevin P., Fernandez-Hidalgo N., Dickerman S., Bouza E., Del Rio A., Lejko-Zupanc T., De Oliveira Ramos A., Iarussi D., Klein J., Chirouze C., Bedimo R., Corey G.R., Fowler Jr. V.G., Gordon D., Devi U., Spelman D., Van Der Meer J.T.M., Kauffman C., Bradley S., Armstrong W., Giannitsioti E., Giamarellou H., Lerakis S., Moreno A., Mestres C.A., Pare C., Garcia De La Maria C., De Lazzario E., Marco F., Gatell J.M., Miro J.M., Almela M., Azqueta M., Jimenez-Exposito M.J., De Benito N., Perez N., Almirante B., Rodriguez De Vera P., Tornos P., Falco V., Claramonte X., Armero Y., Sidani N., Kanj-Sharara S., Kanafani Z., Raglio A., Goglio A., Gnecchi F., Suter F., Valsecchi G., Rizzi M., Ravasio V., Hoen B., Leroy J., Plesiat P., Bernard Y., Casey A., Lambert P., Watkin R., Elliott T., Goissen T., Delahaye A., Vandenesch F., Vizzotti C., Nacinovich F.M., Trivi M., Lombardero M., Cortes C., Casabe J.H., Altclas J., Kogan S., Clara L., Sanchez M., Commerford A., Hansa C., Deetlefs E., Ntsekhe M., Commerford P., Wray D., Steed L.L., Church P., Cantey R., Morris A., Chambers S., Read K., Raymond N., Holland D., Lang S., Kotsanas D., Korman T.M., Peterson G., Purcell J., Southern Jr. P.M., Shah M., Reddy A., Dhar G., Hanlon-Feeney A., Hannan M., Kelly S., Wang A., Woods C.W., Sexton D.J., Benjamin Jr. D., McDonald J.R., Federspiel J., Engemann J.J., Reller L.B., Drew L., Caram L.B., Stryjewski M., Lalani T., Chu V., Mazaheri B., Neuerburg C., Naber C., Athan E., Henry M., Harris O., Alestig E., Olaison L., Wikstrom L., Snygg-Martin U., Francis J., Venugopal K., Nair L., Thomas V., Chaiworramukkun J., Pachirat O., Chetchotisakd P., Suwanich T., Kamarulzaman A., Tamin S.S., Mueller Premru M., Logar M., Orezzi C., Moreno M., Rodriguez-Creixems M., Marin M., Fernandez M., Munoz P., Fernandez R., Delahaye F., Patel M., Dismukes W., Pan A., Caros G., Tribouilloy A.B.M.C., Ramallo V., Raoult D., Thuny F., Habib G., Casalta J.-P., Fournier P.-E., Chipigina N., Kirill O., Vinogradova T., Kulichenko V.P., Butkevich O.M., Lion C., Selton-Suty C., Alla F., Coyard H., Doco-Lecompte T., Durante-Mangoni E., Ragone E., Dialetto G., Tripodi M.F., Utili R., Casillo R., Kumar A.S., Sharma G., Street A., Eisen D.P., McBryde E.S., Grigg L., Abrutyn E., Michelet C., Donnio P.Y., Fortes C.Q., Edathodu J., Al-Hegelan M., Font B., Anguera I., Guma J.R., Cereceda M., Oyonarte M.J., Mella R.M., Garcia P., Jones S.B., Paiva M.G., Tranchesi R.A.D.M., Woon L.L., Lum L.-N., Tan R.-S., Rees D., Kornecny P., Lawrence R., Dever R., Post J., Jones P., Ryan S., Harkness J., Feneley M., Rubinstein E., Strahilewitz J., Ionac A., Mornos C., Dragulescu S., Forno D., Cecchi E., De Rosa F., Imazio M., Trinchero R., Wiesbauer F., Gattringer R., Deans G., Andrasevic A.T., Barsic B., Klinar I., Vincelj J., Bukovski S., Krajinovic V., Stafford J., Baloch K., Redick T., Harding T., Bayer A.S., Durack D.T., Moreillon P., Eykyn S., Morpeth S., Murdoch D., Cabell C.H., Karchmer A.W., Pappas P., Levine D., Nacinovich F., Tattevin P., Fernandez-Hidalgo N., Dickerman S., Bouza E., Del Rio A., Lejko-Zupanc T., De Oliveira Ramos A., Iarussi D., Klein J., Chirouze C., Bedimo R., Corey G.R., Fowler Jr. V.G., Gordon D., Devi U., Spelman D., Van Der Meer J.T.M., Kauffman C., Bradley S., Armstrong W., Giannitsioti E., Giamarellou H., Lerakis S., Moreno A., Mestres C.A., Pare C., Garcia De La Maria C., De Lazzario E., Marco F., Gatell J.M., Miro J.M., Almela M., Azqueta M., Jimenez-Exposito M.J., De Benito N., Perez N., Almirante B., Rodriguez De Vera P., Tornos P., Falco V., Claramonte X., Armero Y., Sidani N., Kanj-Sharara S., Kanafani Z., Raglio A., Goglio A., Gnecchi F., Suter F., Valsecchi G., Rizzi M., Ravasio V., Hoen B., Leroy J., Plesiat P., Bernard Y., Casey A., Lambert P., Watkin R., Elliott T., Goissen T., Delahaye A., Vandenesch F., Vizzotti C., Nacinovich F.M., Trivi M., Lombardero M., Cortes C., Casabe J.H., Altclas J., Kogan S., Clara L., Sanchez M., Commerford A., Hansa C., Deetlefs E., Ntsekhe M., Commerford P., Wray D., Steed L.L., Church P., Cantey R., Morris A., Chambers S., Read K., Raymond N., Holland D., Lang S., Kotsanas D., Korman T.M., Peterson G., Purcell J., Southern Jr. P.M., Shah M., Reddy A., Dhar G., Hanlon-Feeney A., Hannan M., Kelly S., Wang A., Woods C.W., Sexton D.J., Benjamin Jr. D., McDonald J.R., Federspiel J., Engemann J.J., Reller L.B., Drew L., Caram L.B., Stryjewski M., Lalani T., Chu V., Mazaheri B., Neuerburg C., Naber C., Athan E., Henry M., Harris O., Alestig E., Olaison L., Wikstrom L., Snygg-Martin U., Francis J., Venugopal K., Nair L., Thomas V., Chaiworramukkun J., Pachirat O., Chetchotisakd P., Suwanich T., Kamarulzaman A., Tamin S.S., Mueller Premru M., Logar M., Orezzi C., Moreno M., Rodriguez-Creixems M., Marin M., Fernandez M., Munoz P., and Fernandez R.

Abstract

Background: Infective endocarditis caused by non-HACEK (species other than Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, or Kingella species) gram-negative bacilli is rare, is poorly characterized, and is commonly considered to be primarily a disease of injection drug users. Objective(s): To describe the clinical characteristics and outcomes of patients with non-HACEK gram-negative bacillus endocarditis in a large, international, contemporary cohort of patients. Design(s): Observations from the International Collaboration on Infective Endocarditis Prospective Cohort Study (ICE-PCS) database. Setting(s): 61 hospitals in 28 countries. Patient(s): Hospitalized patients with definite endocarditis. Measurements: Characteristics of non-HACEK gram-negative bacillus endocarditis cases were described and compared with those due to other pathogens. Result(s): Among the 2761 case-patients with definite endocarditis enrolled in ICE-PCS, 49 (1.8%) had endocarditis (20 native valve, 29 prosthetic valve or device) due to non-HACEK, gram-negative bacilli. Escherichia coli (14 patients [29%]) and Pseudomonas aeruginosa (11 patients [22%]) were the most common pathogens. Most patients (57%) with non-HACEK gram-negative bacillus endocarditis had health care-associated infection, whereas injection drug use was rare (4%). Implanted endovascular devices were frequently associated with non-HACEK gram-negative bacillus endocarditis compared with other causes of endocarditis (29% vs. 11%; P < 0.001). The in-hospital mortality rate of patients with endocarditis due to non-HACEK gram-negative bacilli was high (24%) despite high rates of cardiac surgery (51%). Limitation(s): Because of the small number of patients with non-HACEK gram-negative bacillus endocarditis in each treatment group and the lack of long-term follow-up, strong treatment recommendations are difficult to make. Conclusion(s): In this large, prospective, multinational

Published
2008

33. Sedation, Sucralfate, and Antibiotic Use Are Potential Means for Protection against Early-Onset Ventilator-Associated Pneumonia.

Author

Tripodi, M. F., Adinolfi, L. E., Ragone, E., Mangoni, E. Durante, Fortunato, R., Iarussi, D., Ruggiero, G., and Utiii, R.

Subjects
PNEUMONIA, SUCRALFATE, ANTIBIOTICS, LUNG diseases, ANTI-infective agents, ANTIBACTERIAL agents
Abstract

To examine risk factors for early-onset ventilator-associated pneumonia (EOP) in patients requiring mechanical ventilation (MV), we performed a prospective cohort study that included 747 patients. Pneumonia was defined as a positive result for a protected quantitative distal sample. EOP was defined as pneumonia that occurred from day 3 to day 7 of MV. Eighty patients (10.7%) experienced EOP. Independent predictors of EOP were male sex (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.18-3.63), actual Glasgow Coma Scale value of 6-13 (OR, 1.95; 95% CI, 1.2-3.18), high Logistic Organ Dysfunction score at day 2 (OR, 1.12 per point; 95% CI, 1.02-1.23), unplanned extubation (OR, 3.19; 95% CI, 1.28-7.92), and sucralfate use (OR, 1.81; 95% CI, 1.01-3.26). Protection occurred with use of aminoglycosides (OR, 0.36; 95% CI, 0.17-0.76), β-lactams and/ or β-lactamase inhibitors (OR, 0.47; 95% CI, 0.28-0.83), or third-generation cephalosporins (OR, 0.33; 95% CI, 0.16-0.74). Sucralfate use and unplanned extubation are independent risk factors for EOP. Use of aminoglycosides, β-lactams/β-lactamase inhibitors, or third-generation cephalosporins protects against EOP. [ABSTRACT FROM AUTHOR]

Published
2004

46. Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated.

Author

Iarussi D, Indolfi P, Pisacane C, Casale F, Martino V, Fusco A, De Rosa E, Di Tullio MT, Calabrò R, Iarussi, Diana, Indolfi, Paolo, Pisacane, Carlo, Casale, Fiorina, Martino, Vincenzo, Fusco, Angela, De Rosa, Emilia, Di Tullio, Maria Teresa, and Calabrò, Raffaele

Abstract

The aim of this report was to evaluate late left ventricular function in survivors of Wilms' tumor and to compare patients treated with anthracyclines with those treated without anthracycline and with normal subjects. Wilms' tumor survivors treated without anthracycline had no myocardial abnormalities. A large percentage of patients treated with anthracycline presented with increased end-systolic wall stress. Results indicate that there is a high incidence of subclinical cardiovascular abnormalities in such patients. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

48. Non-HACEK gram-negative bacillus endocarditis

Author

Morpeth, S, Murdoch, D, Cabell, Ch, Karchmer, Aw, Pappas, P, Levine, D, Nacinovich, F, Tattevin, P, Fernández Hidalgo, N, Dickerman, S, Bouza, E, del Río, A, Lejko Zupanc, T, de Oliveira Ramos, A, Iarussi, D, Klein, J, Chirouze, C, Bedimo, R, Corey, Gr, Fowler VG Jr, Collaborators: Gordon D, International Collaboration on Endocarditis Prospective Cohort Study I. n. v. e. s. t. i. g. a. t. o. r. s., Devi, U, Spelman, D, van der Meer JT, Kauffman, C, Bradley, S, Armstrong, W, Giannitsioti, E, Giamarellou, H, Lerakis, S, del Rio, A, Moreno, A, Mestres, Ca, Paré, C, Garcia de la Maria, C, De Lazzario, E, Marco, F, Gatell, Jm, Miró, Jm, Almela, M, Azqueta, M, Jiménez Expósito MJ, de Benito, N, Perez, N, Almirante, B, Fernandez Hidalgo, N, Rodriguez de Vera, P, Tornos, P, Falcó, V, Claramonte, X, Armero, Y, Sidani, N, Kanj Sharara, S, Kanafani, Z, Raglio, A, Goglio, A, Gnecchi, F, Suter, F, Valsecchi, G, Rizzi, M, Ravasio, V, Hoen, B, Leroy, J, Plesiat, P, Bernard, Y, Casey, A, Lambert, P, Watkin, R, Elliott, T, Patel, M, Dismukes, W, Pan, A, Caros, G, Tribouilloy, Ab, Goissen, T, Delahaye, A, Delahaye, F, Vandenesch, F, Vizzotti, C, Nacinovich, Fm, Marin, M, Trivi, M, Lombardero, M, Cortes, C, Horacio Casabe, J, Altclas, J, Kogan, S, Clara, L, Sanchez, M, Commerford, A, Hansa, C, Deetlefs, E, Ntsekhe, M, Commerford, P, Wray, D, Steed, Ll, Church, P, Cantey, R, Morris, A, Read, K, Raymond, N, Lang, S, Chambers, S, Kotsanas, D, Korman, Tm, Peterson, G, Purcell, J, Southern PM Jr, Shah, M, Reddy, A, Dhar, G, Hanlon Feeney, A, Hannan, M, Kelly, S, Wang, A, Woods, Cw, Sexton, Dj, Benjamin D., Jr, Mcdonald, Jr, Federspiel, J, Engemann, Jj, Reller, Lb, Drew, L, Caram, Lb, Stryjewski, M, Lalani, T, Fowler V., Jr, Chu, V, Mazaheri, B, Neuerburg, C, Naber, C, Athan, E, Henry, M, Harris, O, Alestig, E, Olaison, L, Wikstrom, L, Snygg Martin, U, Francis, J, Venugopal, K, Nair, L, Thomas, V, Chaiworramukkun, J, Pachirat, O, Chetchotisakd, P, Suwanich, T, Kamarulzaman, A, Tamin, Ss, Premru, Mm, Logar, M, Orezzi, C, Moreno, M, Rodríguez Créixems, M, Fernández, M, Muñoz, P, Fernández, R, Ramallo, V, Raoult, D, Thuny, F, Habib, G, Casalta, Jp, Fournier, Pe, Chipigina, N, Kirill, O, Vinogradova, T, Kulichenko, Vp, Butkevich, Om, Lion, C, Alla, F, Coyard, H, Doco Lecompte, T, Durante Mangoni, E, Ragone, E, Dialetto, G, Tripodi, Mf, Utili, R, Casillo, R, Kumar, As, Sharma, G, Dickerman, Sa, Street, A, Eisen, Dp, Mcbryde, Es, Grigg, L, Abrutyn, E, Michelet, C, Donnio, Py, Fortes, Cq, Edathodu, J, Al Hegelan, M, Font, B, Anguera, I, Raimon Guma, J, Cereceda, M, Oyonarte, Mj, Montagna Mella, R, Garcia, P, Braun Jones, S, de Oliveira Ramos AI, Paiva, Mg, de Medeiros RA, Woon, Ll, Lum, Ln, Tan, Rs, Rees, D, Koneçny, P, Lawrence, R, Dever, R, Post, J, Jones, P, Ryan, S, Harkness, J, Feneley, M, Rubinstein, E, Strahilewitz, J, Ionac, A, Mornos, C, Dragulescu, S, Forno, D, Cecchi, E, DE ROSA, Francesco Giuseppe, Imazio, M, Trinchero, R, Wiesbauer, F, Gattringer, R, Deans, G, Andrasevic, At, Barsic, B, Klinar, I, Vincelj, J, Bukovski, S, Krajinovic, V, Cabell, C, Stafford, J, Baloch, K, Redick, T, Harding, T, Bayer, A, Durack, Dt, Corey, R, Moreillon, P, Eykynm, S, and Chu, V.

Subjects
Eikenella corrodens, Microbiology, stomatognathic system, Haemophilus, Gram-Negative Bacteria, Internal Medicine, medicine, Endocarditis, Humans, Prospective Studies, Cardiac Surgical Procedures, Substance Abuse, Intravenous, Cross Infection, biology, business.industry, Gram Negative Bacillus, General Medicine, Endocarditis, Bacterial, Prostheses and Implants, biology.organism_classification, medicine.disease, Anti-Bacterial Agents, Community-Acquired Infections, stomatognathic diseases, Treatment Outcome, Infective endocarditis, Bacteremia, Actinobacillus, bacteria, Cardiobacterium hominis, business, Gram-Negative Bacterial Infections
Abstract

Infective endocarditis caused by non-HACEK (species other than Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, or Kingella species) gram-negative bacilli is rare, is poorly characterized, and is commonly considered to be primarily a disease of injection drug users.To describe the clinical characteristics and outcomes of patients with non-HACEK gram-negative bacillus endocarditis in a large, international, contemporary cohort of patients.Observations from the International Collaboration on Infective Endocarditis Prospective Cohort Study (ICE-PCS) database.61 hospitals in 28 countries.Hospitalized patients with definite endocarditis.Characteristics of non-HACEK gram-negative bacillus endocarditis cases were described and compared with those due to other pathogens.Among the 2761 case-patients with definite endocarditis enrolled in ICE-PCS, 49 (1.8%) had endocarditis (20 native valve, 29 prosthetic valve or device) due to non-HACEK, gram-negative bacilli. Escherichia coli (14 patients [29%]) and Pseudomonas aeruginosa (11 patients [22%]) were the most common pathogens. Most patients (57%) with non-HACEK gram-negative bacillus endocarditis had health care-associated infection, whereas injection drug use was rare (4%). Implanted endovascular devices were frequently associated with non-HACEK gram-negative bacillus endocarditis compared with other causes of endocarditis (29% vs. 11%; P0.001). The in-hospital mortality rate of patients with endocarditis due to non-HACEK gram-negative bacilli was high (24%) despite high rates of cardiac surgery (51%).Because of the small number of patients with non-HACEK gram-negative bacillus endocarditis in each treatment group and the lack of long-term follow-up, strong treatment recommendations are difficult to make.In this large, prospective, multinational cohort, more than one half of all cases of non-HACEK gram-negative bacillus endocarditis were associated with health care contact. Non-HACEK gram-negative bacillus endocarditis is not primarily a disease of injection drug users.

50. Cardiac abnormalities detected by Doppler imaging in patients with neurofibromatosis type 1.

Author

Tedesco, Michele A., Di Salvo, Giovanni, Natale, Francesco, Caputo, Salvatore, Calabrese, Elvira, Grassia, Carolina, Ratti, Gennaro, Iarussi, Diana, Iacono, Aldo, Lama, Giuliana, Tedesco, M A, Di Salvo, G, Natale, F, Caputo, S, Calabrese, E, Grassia, C, Ratti, G, Iarussi, D, Iacono, A, and Lama, G

Subjects
*HEART diseases, *CARDIOLOGY
Abstract

Analyzes myocardial compliance in young patients with neurofibromatosis type I without cardiovascular malformations compared with normal subjects. Characteristics of patients; Echocardiographic characteristics of patients; Doppler tissue parameters.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results